Updated on 2024/03/12

写真a

 
OKUMURA Masayuki
 
Organization
Nagoya University Hospital Radiology Assistant professor of hospital
Title
Assistant professor of hospital

Degree 1

  1. MD, PhD ( 2021.3   Nagoya University ) 

 

Papers 29

  1. Stereotactic radiotherapy for ventricular tachycardia: A study protocol. Reviewed

    Kawamura M, Shimojo M, Inden Y, Kamomae T, Okudaira K, Komada T, Aoki S, Shindo Y, Yasui R, Yanagi Y, Okumura M, Yamada T, Kozai Y, Oie Y, Kato Y, Ishihara S, Murohara T, Naganawa S

    F1000Research   Vol. 12   page: 798   2023.12

     More details

    Language:English   Publisher:F1000Research  

    Background: Currently, the standard curative treatment for ventricular tachycardia (VT) and ventricular fibrillation (VF) is radiofrequency catheter ablation. However, when the VT circuit is deep in the myocardium, the catheter may not be delivered, and a new, minimally invasive treatment using different energies is desired. Methods: This is a protocol paper for a feasibility study designed to provide stereotactic radiotherapy for refractory VT not cured by catheter ablation after at least one catheter ablation. The primary end point is to evaluate the short-term safety of this treatment and the secondary endpoint is to evaluate its efficacy as assessed by the reduction in VT episode. Cyberknife M6 radiosurgery system will be used for treatment, and the prescribed dose to the target will be 25Gy in one fraction. The study will be conducted on three patients. Conclusion: Since catheter ablation is the only treatment option for VT that is covered by insurance in Japan, there is currently no other treatment for VT/VF that cannot be cured by catheter ablation. We hope that this feasibility study will provide hope for patients who are currently under the stress of ICD activation. Trial registration: The study has been registered in the Japan Registry of Clinical Trials (jRCTs042230030).

    DOI: 10.12688/f1000research.138758.2

    Scopus

    PubMed

  2. Optimized radiotherapy treatment strategy for early glottic carcinoma Reviewed

    Ono, T; Itoh, Y; Ishihara, S; Kawamura, M; Oie, Y; Takase, Y; Okumura, M; Oyoshi, H; Nagai, N; Naganawa, S

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 85 ( 2 ) page: 241 - 254   2023.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Nagoya Journal of Medical Science  

    The local control rates of T1 bulky and T2 glottic carcinoma treated via radiation therapy alone are unsatisfactory; thus, we aimed to evaluate the efficacy and safety of our treatment protocol for early glottic carcinoma. Patients with early glottic squamous cell carcinoma treated via radiation therapy from January 2007 to November 2019 were reviewed. Patients were treated with: 63–67.5 Gy/28–30 fractions of radiation therapy alone for T1 non-bulky; concurrent chemoradiotherapy with S-1 and 60 Gy/30 fractions for T1 bulky and T2 favorable; and concurrent chemoradiotherapy with high-dose cisplatin and 66–70 Gy/33–35 fractions for T2 unfavorable glottic carcinoma. Local failure rates were estimated using the cumulative incidence function, overall and disease specific survival rates were estimated using Kaplan-Meier analysis, and adverse events were evaluated. Eighty patients were analyzed; the median age was 69.5 (range, 26–90) years, the median follow-up time for survivors was 40.1 (range, 1.9–128.4) months, and the 3-year local failure, disease specific survival, and overall survival rates were 5.8%, 98.3%, and 94.4%, respectively. In T1 bulky and T2 cases, the local failure rate was significantly lower in the concurrent chemoradiotherapy than in the radiation therapy alone group. Grade 3 acute dermatitis and mucositis were noted in nine and four patients, respectively. There were no acute adverse events of Grade 4 or higher, or late adverse events of Grade 2 or higher. The treatment protocol was effective and well-tolerated; thus, the efficacy of concurrent chemoradiotherapy was suggested in T1 bulky and T2 cases

    DOI: 10.18999/nagjms.85.2.241

    Web of Science

    Scopus

    PubMed

  3. retrospective study of cervical cancer with radiation dose reduction in concurrent chemoradiotherapy

    Nagai, N; Kawamura, M; Ishihara, S; Oie, Y; Kozai, Y; Takase, Y; Okumura, M; Shindo, Y; Yasui, R; Yanagi, Y; Naganawa, S

    RADIOTHERAPY AND ONCOLOGY   Vol. 182   page: S1921 - S1922   2023.5

     More details

  4. The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis. Reviewed

    Sekiguchi K, Sumi M, Saito A, Zenda S, Arahira S, Iino K, Okumura M, Kawai F, Nozawa K

    Breast cancer (Tokyo, Japan)   Vol. 30 ( 1 ) page: 2 - 12   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12282-022-01403-8

    Web of Science

    Scopus

    PubMed

  5. Comprehensive screening for drugs that modify radiation-induced immune responses Reviewed

    Okumura Masayuki, Du Junyan, Kageyama Shun-Ichiro, Yamashita Riu, Hakozaki Yumi, Motegi Atsushi, Hojo Hidehiro, Nakamura Masaki, Hirano Yasuhiro, Okuma Yusuke, Okuma Hitomi S., Tsuchihara Katsuya, Akimoto Tetsuo

    BRITISH JOURNAL OF CANCER   Vol. 126 ( 12 ) page: 1815 - 1823   2022.6

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41416-021-01688-0

    Web of Science

    Scopus

    PubMed

  6. Impacts of the STING-IFNAR1-STAT1-IRF1 pathway on the cellular immune reaction induced by fractionated irradiation. Reviewed

    Du J, Kageyama SI, Yamashita R, Hirata H, Hakozaki Y, Okumura M, Motegi A, Hojo H, Nakamura M, Hirano Y, Sunakawa H, Minamide T, Kotani D, Tanaka K, Yano T, Kojima T, Ohashi A, Tsuchihara K, Akimoto T

    Cancer science   Vol. 113 ( 4 ) page: 1352 - 1361   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.15297

    PubMed

  7. Response to palliative radiotherapy for cancer patients with interstitial lung disease: A physician's perspective.

    Okumura M, Hojo H, Akimoto T

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   Vol. 169   page: 157 - 158   2022.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.radonc.2022.02.003

    Web of Science

    Scopus

    PubMed

  8. Comparative analysis of the immune responses in cancer cells irradiated with X-ray, proton and carbon-ion beams Reviewed

    Du Junyan, Kageyama Shun-Ichiro, Hirata Hidenari, Motegi Atsushi, Nakamura Masaki, Hirano Yasuhiro, Okumura Masayuki, Yamashita Riu, Tsuchihara Katsuya, Hojo Hidehiro, Hirayama Ryoichi, Akimoto Tetsuo

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   Vol. 585   page: 55 - 60   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.bbrc.2021.11.004

    Web of Science

    Scopus

    PubMed

  9. Can we safely lower the RT dose with the use of high dose PF for advanced cervical cancer?

    Kawamura M., Nakahara R., Ishihara S., Oie Y., Takase Y., Okumura M., Ito J., Ono T., Itoh Y., Naganawa S.

    RADIOTHERAPY AND ONCOLOGY   Vol. 161   page: S1064 - S1065   2021.8

     More details

    Language:English   Publishing type:Research paper (international conference proceedings)  

    Web of Science

  10. Evaluation of CTV agreements among planners in intracranial brain tumor

    Takase Y., Kawamura M., Nakahara R., Itoh J., Oie Y., Okumura M., Kamomae T., Itoh Y., Ono T., Naganawa S.

      Vol. 161   page: S864 - S864   2021.8

     More details

    Language:English   Publishing type:Research paper (international conference proceedings)  

    Web of Science

  11. Radiation pneumonitis after palliative radiotherapy in cancer patients with interstitial lung disease. Reviewed

    Okumura M, Hojo H, Nakamura M, Hiyama T, Nakamura N, Zenda S, Motegi A, Hirano Y, Kageyama SI, Parshuram RV, Fujisawa T, Kuno H, Akimoto T

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   Vol. 161   page: 47 - 54   2021.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.radonc.2021.05.026

    PubMed

  12. Comprehensive screening for drugs that modify radiation-induced immune responses

    Okumura M., Du J., Kageyama S., Yamashita R., Motegi A., Hojo H., Nakamura M., Hirano Y., Okuma Y., Okuma H. S., Tsuchihara K., Tetsuo A.

    RADIOTHERAPY AND ONCOLOGY   Vol. 161   page: S336 - S336   2021.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (international conference proceedings)  

    Web of Science

  13. Comparison of a Hybrid IMRT/VMAT technique with non-coplanar VMAT and non-coplanar IMRT for unresectable olfactory neuroblastoma using the RayStation treatment planning system-EUD, NTCP and planning study. Reviewed

    Raturi VP, Motegi A, Zenda S, Nakamura N, Hojo H, Kageyama SI, Okumura M, Rachi T, Ohyoshi H, Tachibana H, Motegi K, Ariji T, Nakamura M, Hirano Y, Hirata H, Akimoto T

    Journal of radiation research   Vol. 62 ( 3 ) page: 540 - 548   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/jrr/rrab010

    PubMed

  14. Identification of the mutation signature of the cancer genome caused by irradiation. Reviewed

    Kageyama SI, Du J, Kaneko S, Hamamoto R, Yamaguchi S, Yamashita R, Okumura M, Motegi A, Hojo H, Nakamura M, Tsuchihara K, Akimoto T

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   Vol. 155   page: 10 - 16   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.radonc.2020.10.020

    PubMed

  15. Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy. Reviewed

    Nakamura M, Kageyama SI, Seki M, Suzuki A, Okumura M, Hojo H, Motegi A, Akimoto T

    Anticancer research   Vol. 41 ( 2 ) page: 829 - 834   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.14835

    PubMed

  16. Fracture Risk is Still High in Patients Receiving Palliative Radiotherapy for High-Risk Femoral Bone Metastases even in Modern Era

    Y.HiranoN.NakamuraS.ZendaA.MotegiH.HojoM.NakamuraS.I.KageyamaM.OkumuraV.P.RaturiT.Akimoto

    International Journal of Radiation Oncology Biology Physics     2020.11

     More details

    Language:English   Publishing type:Research paper (international conference proceedings)  

    DOI: 10.1016/j.ijrobp.2020.07.1368

  17. PO-1261: Radiation pneumonitis after palliative radiotherapy in patients with interstitial lung disease

    M.OkumuraH.HojoN.NakamuraS.ZendaA.MotegiM.NakamuraY.HiranoS.KageyamaV.P.RaturiT.Akimoto

    Radiotherapy and Oncology     2020.11

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (international conference proceedings)  

    DOI: 10.1016/S0167-8140(21)01279-2

  18. Efficacy and safety of accelerated fractionated radiotherapy without elective nodal irradiation for T3N0 glottic cancer without vocal cord fixation Reviewed

    Okumura Masayuki, Motegi Atsushi, Zenda Sadamoto, Nakamura Naoki, Hojo Hidehiro, Nakamura Masaki, Hirano Yasuhiro, Kageyama Shun-ichiro, Arahira Satoko, Parshuram Raturi Vijay, Kuno Hirofumi, Hayashi Ryuichi, Tahara Makoto, Itoh Yoshiyuki, Naganawa Shinji, Akimoto Tetsuo

    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK   Vol. 42 ( 8 ) page: 1775 - 1782   2020.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Doctoral thesis  

    DOI: 10.1002/hed.26092

    Web of Science

    Scopus

    PubMed

  19. Impact of Proton Beam Irradiation of an Anatomic Subsegment of the Liver for Hepatocellular Carcinoma. Reviewed

    Hojo H, Raturi V, Nakamura N, Arahira S, Akita T, Mitsunaga S, Nakamura M, Motegi A, Kageyama SI, Zenda S, Okumura M, Ikeda M, Akimoto T

    Practical radiation oncology   Vol. 10 ( 4 ) page: e264 - e271   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.prro.2019.09.012

    PubMed

  20. Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head. Reviewed

    Raturi VP, Hojo H, Hotta K, Baba H, Takahashi R, Rachi T, Nakamura N, Zenda S, Motegi A, Tachibana H, Ariji T, Motegi K, Nakamura M, Okumura M, Hirano Y, Akimoto T

    Radiation oncology (London, England)   Vol. 15 ( 1 ) page: 157   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s13014-020-01592-6

    PubMed

  21. Prospective evaluation of XRCC-1 Arg194Trp polymorphism as bio-predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation. Reviewed

    Raturi V, Hojo H, Bhatt MLB, Suhel M, Wu CT, Bei Y, Nakamura M, Okumura M, Zhang H, Parmar D, Badajena A, Singh R, Kumar S, Katiyar T, Gaur J

    Head & neck   Vol. 42 ( 5 ) page: 1045 - 1056   2020.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hed.26083

    PubMed

  22. Could excision repair cross-complementing group-1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer? Reviewed

    Raturi VP, Wu CT, Mohammad S, Hojo H, Bei Y, Nakamura M, Okumura M, Rachi T, Singh R, Gupta R, Parmar D, Hasan F, Gaur J, Kishan D, Kumar S, Badajena A, Katepogu P, Shigematsu N

    Asia-Pacific journal of clinical oncology   Vol. 16 ( 2 ) page: e19 - e26   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ajco.13239

    PubMed

  23. Prospective evaluation of the setup errors and its impact on safety margin for cervical cancer pelvic conformal radiotherapy. Reviewed

    Badajena A, Raturi VP, Sirvastava K, Hojo H, Ohyoshi H, Bei Y, Rachi T, Wu CT, Tochinai T, Okumura M, Zhang H, Kouta H, Verma P, Singh G, Anand A, Sachan A

    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology   Vol. 25 ( 2 ) page: 260 - 265   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.rpor.2020.02.006

    PubMed

  24. Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis. Reviewed

    Raturi VP, Tochinai T, Hojo H, Rachi T, Hotta K, Nakamura N, Zenda S, Motegi A, Ariji T, Hirano Y, Baba H, Ohyoshi H, Nakamura M, Okumura M, Bei Y, Akimoto T

    Frontiers in oncology   Vol. 10   page: 517061   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fonc.2020.517061

    PubMed

  25. Palliative Radiation Therapy for Macroscopic Hematuria Caused by Urothelial Cancer. Reviewed

    Zhang H, Hojo H, Parshuram Raturi V, Nakamura N, Nakamura M, Okumura M, Hirano Y, Motegi A, Kageyama SI, Zenda S, Akimoto T

    Palliative medicine reports   Vol. 1 ( 1 ) page: 201 - 207   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1089/pmr.2020.0027

    PubMed

  26. Hypofractionated proton beam therapy for centrally located lung cancer. Reviewed

    Nakamura N, Hotta K, Zenda S, Baba H, Kito S, Akita T, Motegi A, Hojo H, Nakamura M, Parshuram RV, Okumura M, Akimoto T

    Journal of medical imaging and radiation oncology   Vol. 63 ( 4 ) page: 552 - 556   2019.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/1754-9485.12901

    PubMed

  27. Phase I Dose-Escalation Trial of Proton Beam Therapy with Concurrent Full-Dose Chemotherapy for Patients with C stage IB/Ⅱ/Ⅲ (non-T4) Esophageal Squamous Cell Carcinoma

    T.Akimoto1T.Kojima2H.Hojo1M.Onozawa1M.Okumura1M.Nakamura1A.Motegi1K.Hotta1H.Baba1S.Zenda1T.Fujita3N.Nakamura1H.Daiko3

    International Journal of Radiation Oncology Biology Physics     2019.7

     More details

    Language:English   Publishing type:Research paper (international conference proceedings)  

    DOI: 10.1016/j.ijrobp.2019.06.114

  28. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer. Reviewed

    Nakamura M, Kageyama SI, Niho S, Okumura M, Hojo H, Motegi A, Nakamura N, Zenda S, Yoh K, Goto K, Akimoto T

    Clinical lung cancer   Vol. 20 ( 3 ) page: e256 - e264   2019.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cllc.2019.02.021

    PubMed

  29. 女性尿道憩室に発生した尿路上皮癌の1例

    富家 未来 1 , 奥村 真之 1 , 河村 綾希子 1 , 河合 雄一 1 , 服部 良平 2 , 露木 敦士 3 , 伊藤 茂樹 1

    臨床放射線     2017.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.18888/rp.0000000108

▼display all

Books 3

  1. 放射線療法によって起こり得る栄養障害のリスク管理

    奥村真之 全田貞幹( Role: Joint author)

    栄養経営エキスパート  2020.5 

     More details

    Language:Japanese Book type:Textbook, survey, introduction

  2. 放射線治療に伴う皮膚・食道の有害事象に対する予防とケア

    奥村真之 全田貞幹( Role: Joint author)

    月刊薬事  2019.6 

     More details

    Language:Japanese Book type:Textbook, survey, introduction

  3. 最新放射線治療のエビデンスと課題

    奥村 真之 全田 貞幹中村 匡希北條 秀博 茂木 厚 影山 俊一郎 中村 直樹 秋元 哲夫( Role: Joint author)

    腫瘍内科  2019.4 

     More details

    Language:Japanese Book type:Textbook, survey, introduction

Presentations 4

  1. 間質性肺疾患を有するがん患者における緩和照射後の放射線肺臓炎

    奥村真之

    日本放射線腫瘍学会第34回学術大会  2021.11 

     More details

    Event date: 2021.11

    Language:Japanese   Presentation type:Oral presentation (general)  

  2. Comprehensive screening for drugs that modify radiation-induced immune responses International conference

    M.OkumuraJ.DuS.KageyamaR.YamashitaA.MotegiH.HojoM.NakamuraY.HiranoY.OkumaH.S.OkumaK.TsuchiharaA.Tetsuo

    ESTRO 2021   2021.8.29 

     More details

    Event date: 2021.8

    Language:English   Presentation type:Oral presentation (general)  

  3. 肝細胞癌に対するサイバーナイフを用いた体幹部定位放射線治療の遡及的検討

    奥村真之1,3 奥田隆仁1 鈴木淳司2 高瀬裕樹1,3 川村麻里子3 石原俊一3 長縄慎二3

    日本医学放射線学会第169回中部地方会  2021.7.3 

     More details

    Event date: 2021.7

    Language:Japanese   Presentation type:Oral presentation (general)  

  4. Radiation pneumonitis after palliative radiotherapy in patients with interstitial lung disease International conference

    M.OkumuraH.HojoN.NakamuraS.ZendaA.MotegiM.NakamuraY.HiranoS.KageyamaV.P.RaturiT.Akimoto

    ESTRO 2020  2020.11.28 

     More details

    Event date: 2020.11 - 2020.12

    Language:English   Presentation type:Poster presentation  

KAKENHI (Grants-in-Aid for Scientific Research) 1

  1. 放射線誘導免疫応答のメカニズム解明および免疫放射線治療の最適化

    Grant number:21K15804  2021.4 - 2024.3

    科学研究費助成事業  若手研究

    奥村 真之

      More details

    Authorship:Principal investigator 

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    本研究では、あらゆる化合物の中から放射線誘導免疫応答を修飾する化合物を見出し、既知・未知のメカニズムを考察することが目的である。
    レポーターアッセイを基に構築したHigh Throughput Systemを用いて、1.臨床承認薬、2.キナーゼ阻害剤、3.未承認薬を含む新規化合物のそれぞれに対し段階的にスクリーニングを行う。
    放射線誘導免疫応答を評価するHigh Throughput Screening系を構築した。その系の妥当性についてはPARP阻害剤をpositive control、副腎皮質ステロイドをnegative controlとした検証を行い、それぞれ放射線単独と比較して免疫応答の活性化/抑制が確認され、実験系は妥当であると判断した。
    上記実験系を用いて臨床承認薬のほぼすべてを網羅したFDA承認薬剤(2595化合物)をスクリーニングし、放射線誘導がん免疫応答への影響を定量化・カタログ化した。さらに、薬剤併用の結果生じる免疫応答修飾のメカニズムをトランスクリプトームにて解析した。
    薬剤スクリーニングの結果としては、19%の薬剤で放射線単独と比較して免疫応答が活性化、15%では免疫応答が半分以下に抑制された。抗がん剤についてはその作用機序ごとに免疫応答の活性化/抑制の傾向が分かれた。肺がんの同時化学放射線療法に使用される薬剤に着目すると、微小管脱重合阻害剤・白金製剤・トポイソメラーゼ阻害剤は免疫応答を活性化/維持し、ピリミジン代謝拮抗剤・微小管重合阻害剤・副腎皮質ホルモン剤は免疫応答を半分以下に抑制した。RNA seqでのGene enrichment analysisではこれらの放射線誘導免疫応答が主にType Iインターフェロン応答によるものであることが確認された。
    この内容について2021年の欧州放射線腫瘍学会(ESTRO 2021)のPoster Discussionにて発表を行った(DOI:10.1016/S0167-8140(21)07327-8)。また、学術雑誌に投稿し、掲載に至った(British Journal of Cancer, PMID: 35184156, DOI: 10.1038/s41416-021-01688-0)。
    1年目に予定していたFDA承認薬ライブラリの検証については結果を得ることができ、さらに学会発表、学術誌掲載に至っており、おおむね順調と判断した。
    一方、本基礎研究結果と臨床試験結果との相関性の確認はまだ十分でなく、2年目以降の課題である。
    今後はまず、本研究で評価した免疫応答が、周囲の免疫細胞の活性化を引き起こすことを検証するためにヒト末梢血単核細胞のmigration assayを行っていく。
    さらにはキナーゼ阻害剤ライブラリを用いて放射線誘導免疫応答を評価し、免疫を増強・抑制する主要なpathwayを同定し、新規治療につなげる。
    また、東京大学創薬機構ライブラリ(東京大学が企業と提携し作成しているオーファンドラッグ、新規化合物を含む40万化合物のライブラリ)を用いて放射線誘導免疫応答を増強・抑制する化合物をスクリーニングすることで新規ターゲット探索を行う。